Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 440

1.

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE; CONDI-2/ERIC-PPCI Investigators.

Lancet. 2019 Sep 6. pii: S0140-6736(19)32039-2. doi: 10.1016/S0140-6736(19)32039-2. [Epub ahead of print]

2.

Role of Caspase 1 in Ischemia/Reperfusion Injury of the Myocardium.

Rauf A, Shah M, Yellon DM, Davidson SM.

J Cardiovasc Pharmacol. 2019 Sep;74(3):194-200. doi: 10.1097/FJC.0000000000000694.

PMID:
31356550
3.

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart.

Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM.

JACC Basic Transl Sci. 2019 Jan 30;4(1):15-26. doi: 10.1016/j.jacbts.2018.10.002. eCollection 2019 Feb.

4.

Stromal cell-derived factor-1α signals via the endothelium to protect the heart against ischaemia-reperfusion injury.

Bromage DI, Taferner S, He Z, Ziff OJ, Yellon DM, Davidson SM.

J Mol Cell Cardiol. 2019 Mar;128:187-197. doi: 10.1016/j.yjmcc.2019.02.002. Epub 2019 Feb 7.

5.

Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential.

Takov K, Yellon DM, Davidson SM.

J Extracell Vesicles. 2018 Dec 28;8(1):1560809. doi: 10.1080/20013078.2018.1560809. eCollection 2019.

6.

Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week.

Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D; CARDIOPROTECTION COST Action (CA16225).

J Am Coll Cardiol. 2019 Jan 8;73(1):89-99. doi: 10.1016/j.jacc.2018.09.086. Review.

7.

Protection From Cardiac Ischemia-Reperfusion Injury by Epigenetic Regulation of NADPH Oxidase.

Davidson SM, Yellon DM.

Circulation. 2018 Dec 11;138(24):2837-2840. doi: 10.1161/CIRCULATIONAHA.118.036697. No abstract available.

PMID:
30565995
8.

Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning.

Davidson SM, Riquelme JA, Zheng Y, Vicencio JM, Lavandero S, Yellon DM.

Sci Rep. 2018 Oct 26;8(1):15885. doi: 10.1038/s41598-018-34357-z.

9.

The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology.

Davidson SM, Arjun S, Basalay MV, Bell RM, Bromage DI, Bøtker HE, Carr RD, Cunningham J, Ghosh AK, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Maddock H, Ovize M, Walker M, Wiart M, Yellon DM.

Basic Res Cardiol. 2018 Oct 11;113(6):43. doi: 10.1007/s00395-018-0704-z.

10.

Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Bøtker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femminò S, García-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhäuser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schlüter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G.

Basic Res Cardiol. 2018 Aug 17;113(5):39. doi: 10.1007/s00395-018-0696-8. Review. No abstract available.

11.

Apoptosis, A Double-Edge Sword!

Rossello X, Yellon DM.

JACC Basic Transl Sci. 2017 Aug 28;2(4):498. doi: 10.1016/j.jacbts.2017.07.008. eCollection 2017 Aug. No abstract available.

12.

Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects.

Basalay MV, Davidson SM, Gourine AV, Yellon DM.

Basic Res Cardiol. 2018 Jun 1;113(4):25. doi: 10.1007/s00395-018-0684-z. Review.

13.

Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.

Maulik A, Davidson SM, Piotrowska I, Walker M, Yellon DM.

Cardiovasc Drugs Ther. 2018 Jun;32(3):245-253. doi: 10.1007/s10557-018-6793-y.

14.

The GTN patch: a simple and effective new approach to cardioprotection?

Yellon DM, He Z, Khambata R, Ahluwalia A, Davidson SM.

Basic Res Cardiol. 2018 Apr 17;113(3):20. doi: 10.1007/s00395-018-0681-2.

15.

Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute.

Rossello X, He Z, Yellon DM.

Cardiovasc Drugs Ther. 2018 Apr;32(2):127-133. doi: 10.1007/s10557-018-6788-8.

16.

Cardioprotection - is no the answer? A renewed look at nitric oxide signalling in cardiomyocytes.

Davidson SM, Yellon DM.

Cardiovasc Res. 2018 May 1;114(6):773-775. doi: 10.1093/cvr/cvy073. No abstract available.

PMID:
29584817
17.

The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway.

Do Carmo H, Arjun S, Petrucci O, Yellon DM, Davidson SM.

Cardiovasc Drugs Ther. 2018 Apr;32(2):165-168. doi: 10.1007/s10557-018-6781-2.

18.

Confounding factors in vesicle uptake studies using fluorescent lipophilic membrane dyes.

Takov K, Yellon DM, Davidson SM.

J Extracell Vesicles. 2017 Oct 12;6(1):1388731. doi: 10.1080/20013078.2017.1388731. eCollection 2017.

19.

Xenon: A Noble Member of the Cardioprotection Club.

Yellon DM, Rossello X.

J Am Coll Cardiol. 2017 Nov 28;70(21):2661-2662. doi: 10.1016/j.jacc.2017.10.004. No abstract available.

20.

Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion.

Rossello X, Riquelme JA, Davidson SM, Yellon DM.

J Cell Mol Med. 2018 Feb;22(2):926-935. doi: 10.1111/jcmm.13394. Epub 2017 Nov 20.

21.

The RISK pathway and beyond.

Rossello X, Yellon DM.

Basic Res Cardiol. 2017 Nov 15;113(1):2. doi: 10.1007/s00395-017-0662-x. Print 2018 Jan 8. Review.

22.

Exosomes and cardioprotection - A critical analysis.

Davidson SM, Yellon DM.

Mol Aspects Med. 2018 Apr;60:104-114. doi: 10.1016/j.mam.2017.11.004. Epub 2017 Nov 15. Review.

23.

The role of PI3Kα isoform in cardioprotection.

Rossello X, Riquelme JA, He Z, Taferner S, Vanhaesebroeck B, Davidson SM, Yellon DM.

Basic Res Cardiol. 2017 Oct 17;112(6):66. doi: 10.1007/s00395-017-0657-7.

24.

Therapeutic strategies utilizing SDF-1α in ischaemic cardiomyopathy.

Ziff OJ, Bromage DI, Yellon DM, Davidson SM.

Cardiovasc Res. 2018 Mar 1;114(3):358-367. doi: 10.1093/cvr/cvx203. Review.

25.

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Bell RM, Yellon DM.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):435-437. doi: 10.1016/S2213-8587(17)30314-5. Epub 2017 Oct 10. No abstract available.

PMID:
29030201
26.

Assessing the effects of mitofusin 2 deficiency in the adult heart using 3D electron tomography.

Beikoghli Kalkhoran S, Hall AR, White IJ, Cooper J, Fan Q, Ong SB, Hernández-Reséndiz S, Cabrera-Fuentes H, Chinda K, Chakraborty B, Dorn GW 2nd, Yellon DM, Hausenloy DJ.

Physiol Rep. 2017 Sep;5(17). pii: e13437. doi: 10.14814/phy2.13437.

27.

Combination Therapy to Target Reperfusion Injury After ST-Segment-Elevation Myocardial Infarction: A More Effective Approach to Cardioprotection.

Hausenloy DJ, Yellon DM.

Circulation. 2017 Sep 5;136(10):904-906. doi: 10.1161/CIRCULATIONAHA.117.029859. No abstract available.

PMID:
28874421
28.

Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply.

Hausenloy DJ, Garcia-Dorado D, Erik Bøtker H, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JPG, Van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P.

Cardiovasc Res. 2017 Sep 1;113(11):1418-1419. doi: 10.1093/cvr/cvx137. No abstract available.

PMID:
28859295
29.

Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of non-diabetic exosomes in vitro.

Davidson SM, Riquelme JA, Takov K, Vicencio JM, Boi-Doku C, Khoo V, Doreth C, Radenkovic D, Lavandero S, Yellon DM.

J Cell Mol Med. 2018 Jan;22(1):141-151. doi: 10.1111/jcmm.13302. Epub 2017 Aug 25.

30.

Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality.

Bulluck H, Maiti R, Chakraborty B, Candilio L, Clayton T, Evans R, Jenkins DP, Kolvekar S, Kunst G, Laing C, Nicholas J, Pepper J, Yellon DM, Hausenloy DJ.

Heart. 2017 Aug 9. pii: heartjnl-2017-311760. doi: 10.1136/heartjnl-2017-311760. [Epub ahead of print]

31.

Unique morphological characteristics of mitochondrial subtypes in the heart: the effect of ischemia and ischemic preconditioning.

Kalkhoran SB, Munro P, Qiao F, Ong SB, Hall AR, Cabrera-Fuentes H, Chakraborty B, Boisvert WA, Yellon DM, Hausenloy DJ.

Discoveries (Craiova). 2017 Jan-Mar;5(1). pii: e71. doi: 10.15190/d.2017.1.

32.

Letter by Takov et al Regarding Article, "Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice".

Takov K, Yellon DM, Davidson SM.

Circ Res. 2017 May 26;120(11):e46-e47. doi: 10.1161/CIRCRESAHA.117.311127. No abstract available.

PMID:
28546360
33.

Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance.

Dongworth RK, Campbell-Washburn AE, Cabrera-Fuentes HA, Bulluck H, Roberts T, Price AN, Hernández-Reséndiz S, Ordidge RJ, Thomas DL, Yellon DM, Lythgoe MF, Hausenloy DJ.

Sci Rep. 2017 May 23;7(1):2271. doi: 10.1038/s41598-017-02544-z.

34.

Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.

Hausenloy DJ, Garcia-Dorado D, Bøtker HE, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JPG, Van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P.

Cardiovasc Res. 2017 May 1;113(6):564-585. doi: 10.1093/cvr/cvx049. Review.

PMID:
28453734
35.

A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies.

Bromage DI, Taferner S, Pillai M, Yellon DM, Davidson SM.

PLoS One. 2017 Apr 5;12(4):e0174447. doi: 10.1371/journal.pone.0174447. eCollection 2017.

36.

Ventilation strategy has a major influence on remote ischaemic preconditioning in mice.

Davidson SM, He Z, Dyson A, Bromage DI, Yellon DM.

J Cell Mol Med. 2017 Oct;21(10):2426-2431. doi: 10.1111/jcmm.13164. Epub 2017 Apr 4.

37.

Remote Ischaemic Conditioning in Carotid Artery Stenting: Another Step on the Journey Toward Clinical Translatability?

Bell RM, Yellon DM.

Circulation. 2017 Apr 4;135(14):1336-1338. doi: 10.1161/CIRCULATIONAHA.117.027474. No abstract available.

PMID:
28373526
38.

Reply to "Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei".

Bulluck H, Nicholas J, Crimi G, White SK, Ludman AJ, Pica S, Raineri C, Cabrera-Fuentes HA, Yellon DM, Rodriguez-Palomares J, Garcia-Dorado D, Hausenloy DJ.

Int J Cardiol. 2017 May 15;235:192-193. doi: 10.1016/j.ijcard.2017.02.112. No abstract available.

PMID:
28342493
39.

Diagnostic performance of T1 and T2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients.

Bulluck H, Rosmini S, Abdel-Gadir A, Bhuva AN, Treibel TA, Fontana M, Gonzalez-Lopez E, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Moon JC, Hausenloy DJ.

J Magn Reson Imaging. 2017 Sep;46(3):877-886. doi: 10.1002/jmri.25638. Epub 2017 Feb 15.

40.

Anthracycline Chemotherapy and Cardiotoxicity.

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM.

Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75. doi: 10.1007/s10557-016-6711-0. Review.

41.

Intrinsic cardiac ganglia and acetylcholine are important in the mechanism of ischaemic preconditioning.

Pickard JMJ, Burke N, Davidson SM, Yellon DM.

Basic Res Cardiol. 2017 Mar;112(2):11. doi: 10.1007/s00395-017-0601-x. Epub 2017 Jan 13.

42.

Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis.

Bromage DI, Pickard JM, Rossello X, Ziff OJ, Burke N, Yellon DM, Davidson SM.

Cardiovasc Res. 2017 Mar 1;113(3):288-297. doi: 10.1093/cvr/cvw219. Review.

43.

Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment-Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling.

Bulluck H, Rosmini S, Abdel-Gadir A, White SK, Bhuva AN, Treibel TA, Fontana M, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Kellman P, Moon JC, Hausenloy DJ.

Circ Cardiovasc Imaging. 2016 Oct;9(10). pii: e004940.

44.

A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?

Rossello X, Yellon DM.

Int J Cardiol. 2017 Feb 1;228:198-200. doi: 10.1016/j.ijcard.2016.11.246. Epub 2016 Nov 12.

PMID:
27865185
45.

Exosomes and Cardiovascular Protection.

Davidson SM, Takov K, Yellon DM.

Cardiovasc Drugs Ther. 2017 Feb;31(1):77-86. doi: 10.1007/s10557-016-6698-6. Review.

46.

Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery.

Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D.

Basic Res Cardiol. 2016 Nov;111(6):70. Epub 2016 Oct 20. Review.

47.

From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research".

Cabrera-Fuentes HA, Aragones J, Bernhagen J, Boening A, Boisvert WA, Bøtker HE, Bulluck H, Cook S, Di Lisa F, Engel FB, Engelmann B, Ferrazzi F, Ferdinandy P, Fong A, Fleming I, Gnaiger E, Hernández-Reséndiz S, Kalkhoran SB, Kim MH, Lecour S, Liehn EA, Marber MS, Mayr M, Miura T, Ong SB, Peter K, Sedding D, Singh MK, Suleiman MS, Schnittler HJ, Schulz R, Shim W, Tello D, Vogel CW, Walker M, Li QO, Yellon DM, Hausenloy DJ, Preissner KT.

Basic Res Cardiol. 2016 Nov;111(6):69. Epub 2016 Oct 14. Review.

48.

Cardioprotection: The Disconnect Between Bench and Bedside.

Rossello X, Yellon DM.

Circulation. 2016 Aug 23;134(8):574-5. doi: 10.1161/CIRCULATIONAHA.116.022829. Review. No abstract available.

PMID:
27550967
49.

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post-Reperfused ST-Elevation Myocardial Infarction.

Bulluck H, Rosmini S, Abdel-Gadir A, White SK, Bhuva AN, Treibel TA, Fontana M, Gonzalez-Lopez E, Reant P, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Kellman P, Moon JC, Hausenloy DJ.

J Am Heart Assoc. 2016 Jul 11;5(7). pii: e003555. doi: 10.1161/JAHA.116.003555.

50.

A critical review on the translational journey of cardioprotective therapies!

Rossello X, Yellon DM.

Int J Cardiol. 2016 Oct 1;220:176-84. doi: 10.1016/j.ijcard.2016.06.131. Epub 2016 Jun 25. Review.

PMID:
27379920

Supplemental Content

Loading ...
Support Center